MCID: ORP003
MIFTS: 55

Oropharynx Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Oropharynx Cancer

MalaCards integrated aliases for Oropharynx Cancer:

Name: Oropharynx Cancer 12 15 17
Oropharyngeal Cancer 12 37 55 15
Malignant Neoplasm of Oropharynx 12 72 33
Oropharyngeal Carcinoma 12 72
Primary Malignant Neoplasm of Lateral Wall of Oropharynx 12
Malignant Neoplasm of Junctional Region of Oropharynx 12
Malignant Neoplasm of Posterior Wall of Oropharynx 12
Malignant Neoplasm of Lateral Wall of Oropharynx 12
Malignant Tumor of Posterior Wall of Oropharynx 12
Malignant Tumour of Mesopharynx 12
Malignant Oropharyngeal Tumor 12
Malignant Tumor of Oropharynx 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8557
KEGG 37 H01559
NCIt 50 C7398
SNOMED-CT 68 93933005 93971002
UMLS 72 C0153382 C0153388 C0153389 more

Summaries for Oropharynx Cancer

KEGG : 37
Oropharyngeal cancer is a generic term that includes tumors arising within the anatomic confines of the posterior pharyngeal wall, soft palate, tonsillar region and posterior one-third (base) of the tongue. The vast majority of these tumors (>95%) includes squamous cell carcinomas of mucosal origin. Oropharyngeal squamous cell carcinomas (OPSCCs) are traditionally categorized as head and neck squamous cell carcinoma (HNSCC). High-risk human papillomavirus (HR-HPV) is now recognised as a causative agent in a subset of OPSCCs. HPV-driven OPSCC and tobacco- and alcohol-related OPSCC are biologically distinct entities. In the former, p53 and pRb are both inactivated at the protein level by, respectively, E6 and E7 viral oncoproteins. The majority of HPV-negative tumors, instead, harbor mutations in the TP53 gene, an increased epidermal growth factor receptor (EGFR) gene copy number and higher EGFR expression by immunohistochemistry (IHC).

MalaCards based summary : Oropharynx Cancer, also known as oropharyngeal cancer, is related to anus cancer and tongue cancer. An important gene associated with Oropharynx Cancer is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs sodium fluoride and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include tongue, lymph node and testes, and related phenotypes are homeostasis/metabolism and growth/size/body region

Disease Ontology : 12 A pharynx cancer that is located in the oropharynx.

Wikipedia : 75 Oropharyngeal cancer is a disease in which cancer form in the tissues of the throat (oropharynx). The... more...

Related Diseases for Oropharynx Cancer

Diseases related to Oropharynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 354)
# Related Disease Score Top Affiliating Genes
1 anus cancer 30.6 SERPINB3 KRT7 KRT5 CDKN2A
2 tongue cancer 30.5 TP53 MMP8 CDKN2A CDH1
3 tongue disease 30.4 TP53 CDKN2A CDH1
4 oral cancer 30.3 TP53 EGFR CDKN2A CDH1 ADH1C
5 papilloma 30.2 TP53 KRT7 KRT5 KRT14 CDKN2A
6 tongue squamous cell carcinoma 30.2 TP53 CDKN2A CDH1
7 sarcoma, synovial 30.2 KRT7 KIT CDH1
8 nasopharyngeal carcinoma 30.2 TP53 EGFR CDKN2A CDH1
9 squamous cell carcinoma, head and neck 30.2 TP53 ERBB2 EGFR CDKN2A CDH1
10 larynx cancer 30.1 TP53 EGFR CDKN2A
11 cervix uteri carcinoma in situ 30.0 TP53 GP5 CDKN2A
12 small cell carcinoma 29.9 TP53 KRT7 KIT EGFR CDKN2A
13 cervical squamous cell carcinoma 29.7 TYMP TP53 SERPINB3 CDKN2A CDH1
14 squamous cell carcinoma 29.6 TP53 SERPINB3 ERBB2 EGFR CDKN2A CDH1
15 esophageal cancer 29.3 TYMP TP53 ERBB2 EGFR CDKN2A CDH1
16 cervical cancer 29.0 TYMP TP53 SERPINB3 KRT5 KRT14 ERBB2
17 oral cavity cancer 28.8 TP53 MAML2 ERBB2 EGFR CRTC1 CDH1
18 lung cancer susceptibility 3 28.8 TYMP TP53 KRT7 ERBB2 EGFR CDKN2A
19 in situ carcinoma 28.6 TP53 KRT5 KRT14 ERBB2 EGFR CDKN2A
20 pharynx cancer 28.4 TP53 NFIB MYBL1 KIT EGFR CDKN2A
21 adenoid cystic carcinoma 27.7 TP53 NFIB MYBL1 KRT7 KRT5 KRT14
22 tonsil cancer 27.3 TP53 NFIB MYBL1 MAML2 KRT7 KRT5
23 oropharyngeal cancer, childhood 12.3
24 obsolete: hiv-related oropharyngeal cancer 12.3
25 cutaneous telangiectasia and cancer syndrome, familial 12.2
26 brain ependymoma 10.7 TP53 EGFR
27 lacrimal system cancer 10.7 NFIB MAML2
28 jejunal cancer 10.6 KRT7 KIT
29 malignant peritoneal mesothelioma 10.6 EGFR CDKN2A
30 bladder squamous cell carcinoma 10.6 TP53 CDKN2A
31 optic nerve sheath meningioma 10.6 KRT5 CDKN2A
32 balloon cell malignant melanoma 10.6 KRT7 KRT5
33 vulvar intraepithelial neoplasia 10.6 TP53 KRT7
34 lymphoepithelioma-like thymic carcinoma 10.6 KRT5 KIT CDKN2A
35 breast papillomatosis 10.6 ERBB2 CDKN2A
36 keratinizing squamous cell carcinoma 10.6 TP53 KRT5 CDKN2A
37 adenoid basal cell carcinoma 10.6 KRT7 KIT CDKN2A
38 cerebral convexity meningioma 10.6 TP53 CDH1
39 verrucous carcinoma 10.6 TYMP TP53 CDKN2A
40 esophageal adenosquamous carcinoma 10.6 KRT5 CDH1
41 bladder carcinoma in situ 10.6 TP53 KRT7 CDKN2A
42 nasal cavity adenocarcinoma 10.6 TP53 KRT7 CDKN2A
43 glycogen-rich clear cell breast carcinoma 10.6 TP53 KRT7 CDKN2A
44 fallopian tube endometrioid adenocarcinoma 10.6 ERBB2 CDKN2A
45 inverted transitional papilloma 10.6 KRT7 KRT5 CDKN2A
46 optic nerve neoplasm 10.6 TP53 KRT5 CDKN2A
47 endocervical adenocarcinoma 10.6 TP53 KRT7 CDKN2A
48 benign mesothelioma 10.6 KRT7 KRT5
49 ceruminoma 10.5 KRT7 KRT5 KIT
50 gastric papillary adenocarcinoma 10.5 TP53 ERBB2

Comorbidity relations with Oropharynx Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Oropharynx Cancer:



Diseases related to Oropharynx Cancer

Symptoms & Phenotypes for Oropharynx Cancer

MGI Mouse Phenotypes related to Oropharynx Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.24 ADH1C CDH1 CDKN2A CRTC1 EGFR ERBB2
2 growth/size/body region MP:0005378 10.22 ADH1C CDH1 CDKN2A CRTC1 EGFR ERBB2
3 endocrine/exocrine gland MP:0005379 10.17 CDH1 CDKN2A CRTC1 EGFR ERBB2 KIT
4 digestive/alimentary MP:0005381 10.11 CDH1 CDKN2A EGFR ERBB2 KIT KRT14
5 craniofacial MP:0005382 10.02 EGFR ERBB2 KIT KRT14 KRT5 NFIB
6 integument MP:0010771 9.97 CDH1 CDKN2A EGFR ERBB2 KIT KRT14
7 neoplasm MP:0002006 9.86 CDH1 CDKN2A EGFR ERBB2 KIT KRT14
8 reproductive system MP:0005389 9.65 CDH1 CDKN2A CRTC1 EGFR ERBB2 KIT
9 pigmentation MP:0001186 9.55 CDKN2A EGFR KIT KRT14 TP53
10 respiratory system MP:0005388 9.17 CDKN2A EGFR ERBB2 KIT KRT14 NFIB

Drugs & Therapeutics for Oropharynx Cancer

Drugs for Oropharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 187)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 sodium fluoride Approved Phase 4 7681-49-4
2
Nicotine Approved Phase 4 54-11-5 942 89594
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
5 Cariostatic Agents Phase 4
6 Listerine Phase 4
7 Psychotropic Drugs Phase 4
8 Nicotinic Agonists Phase 4
9 Cholinergic Agents Phase 4
10 Central Nervous System Stimulants Phase 4
11 Liver Extracts Phase 4
12 Antidepressive Agents Phase 4
13 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
14 Antidepressive Agents, Second-Generation Phase 4
15 Cytochrome P-450 Enzyme Inhibitors Phase 4
16 Dopamine Agents Phase 4
17 Neurotransmitter Uptake Inhibitors Phase 4
18 Dopamine Uptake Inhibitors Phase 4
19 Mitomycins Phase 4
20
Gabapentin Approved, Investigational Phase 3 60142-96-3 3446
21
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
22
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
23
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
24
nivolumab Approved Phase 3 946414-94-4
25
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
26
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
27
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
28
Icodextrin Approved, Investigational Phase 3 337376-15-5
29
Durvalumab Approved, Investigational Phase 3 1428935-60-7
30 Kava Approved, Investigational, Nutraceutical Phase 3 9000-38-8
31
Lobeline Investigational Phase 2, Phase 3 90-69-7
32
Tremelimumab Investigational Phase 3 745013-59-6
33 Tranquilizing Agents Phase 3
34 Anti-Anxiety Agents Phase 3
35 Anticonvulsants Phase 3
36 Antimanic Agents Phase 3
37 Excitatory Amino Acid Antagonists Phase 3
38 Excitatory Amino Acids Phase 3
39 Respiratory System Agents Phase 2, Phase 3
40 Muscarinic Agonists Phase 2, Phase 3
41 Immunoglobulin G Phase 2, Phase 3
42 Antibodies, Monoclonal Phase 3
43 Pharmaceutical Solutions Phase 3
44
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
45
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
46
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
47
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
48
Indinavir Approved Phase 2 150378-17-9 5362440
49
Trioxsalen Approved Phase 2 3902-71-4 5585
50
Valproic acid Approved, Investigational Phase 2 99-66-1 3121

Interventional clinical trials:

(show top 50) (show all 208)
# Name Status NCT ID Phase Drugs
1 Essential Oils With and Without Alcohol: in Vivo Antibacterial Effect Unknown status NCT03146390 Phase 4 Essential oils;Alcohol free essential oils
2 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
3 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
4 Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer Recruiting NCT03691441 Phase 4 Chemotherapy
5 Effects of the Bilateral Mandibular Nerve Block (V3) in Mandibular Osteotomy: a Prospective, Randomized, Double-blind Versus Placebo Study Unknown status NCT02618993 Phase 3
6 Randomized Phase III, Double-Blind, Placebo Controlled Study of Prophylactic Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma Unknown status NCT03269344 Phase 3 Gabapentin;Placebo Oral Capsule
7 Brief Intraoperative Electrical Stimulation for Prevention of Shoulder Dysfunction After Oncologic Neck Dissection (ESSAN): a Double-blinded, Randomized Control Trial Unknown status NCT02268344 Phase 3
8 Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state) Unknown status NCT00964977 Phase 3
9 A Phase III Study to Test the Efficacy and Safety of GM-CSF to Reduce the Severity and Duration of Mucosal Injury and Pain (Mucositis) Associated With Curative Radiation Therapy in Head and Neck Cancer Patients Completed NCT00008398 Phase 3
10 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
11 A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
12 A Pilot Study to Compare the Nicotine Lozenge and Tobacco-Free Snuff for Smokeless Tobacco Reduction Completed NCT01018394 Phase 2, Phase 3 nicotine lozenges;tobacco-free snuff
13 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
14 A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA Recruiting NCT03811015 Phase 2, Phase 3 Cisplatin
15 DART-HPV: A Phase III Evaluation of De-escalated Adjuvant Radiation Therapy for HPV-Associated Oropharynx Cancer Recruiting NCT02908477 Phase 3 Docetaxel;Cisplatin
16 A Phase III Randomized Trial of Post-operative Adjuvant Nivolumab and Concomitant Chemo-radiotherapy in High-risk Patients With Resected Squamous Cell Carcinoma of Head and Neck Recruiting NCT03576417 Phase 3 Cisplatin;Nivolumab
17 A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer Recruiting NCT03952585 Phase 2, Phase 3 Cisplatin
18 A Phase II/III Trial of Risk-stratified, Reduced Intensity Adjuvant Treatment in Patients Undergoing Transoral Surgery for Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer Recruiting NCT02215265 Phase 3 Cisplatin
19 Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin Recruiting NCT03258554 Phase 2, Phase 3
20 Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck Recruiting NCT01893307 Phase 2, Phase 3
21 Definitive Chemo-Radiotherapy With or Without Up-front Neck Dissection for Regionally Advanced Head and Neck Squamous Cell Carcinoma: A Phase III Multi-center Prospective Randomized Controlled Trial With Two Additional Observational Cohorts Recruiting NCT02918955 Phase 3 Chemotherapy (Cisplatin)
22 Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer Active, not recruiting NCT01302834 Phase 3 cisplatin
23 Adjuvant De-escalation, Extracapsular Spread, P16+, Transoral (ADEPT) Trial for Oropharynx Malignancy Active, not recruiting NCT01687413 Phase 3 Cisplatin
24 Phase III Trial Testing the Benefit of Intensity-modulated Radiotherapy With Weekly Replanifications Versus Intensity Modulated Radiotherapy With Only One Planification in Locally Advanced Oropharynx Carcinoma for Decreasing Xerostomia Active, not recruiting NCT01874587 Phase 3
25 The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer Active, not recruiting NCT01706939 Phase 3 Carboplatin
26 A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Active, not recruiting NCT02369874 Phase 3 MEDI4736;MEDI4736 + Tremelimumab;Standard of Care
27 Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia Active, not recruiting NCT01266044 Phase 3
28 A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer Active, not recruiting NCT00956007 Phase 3
29 Patient Reported Outcomes in Term of Swallowing and Quality of Life After Prophylactic Versus Reactive Percutaneous Endoscopic Gastrostomy Tube Placement in Advanced Oropharyngeal Cancer Patients Treated With Definitive Chemo-radiotherapy Not yet recruiting NCT04019548 Phase 3 Cisplatin injection
30 Randomized Evaluation of a Phytopharmaceutical in Prevention of Severe Oral Mucositis in Patients Receiving Radiotherapy for Oral Cavity, Oropharynx, Hypopharynx, or Cavum Cancer Terminated NCT01066741 Phase 3 Homeodent®;1.4% Sodium Bicarbonate solution
31 Randomized Phase III Trial on Postoperative Chemoradiation in Combination With Anti EGFR-Antibody Versus Postoperative Chemoradiation in Head and Neck Squamous Cell Carcinomas (HNSCC) With High Risk of Locoregional Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
32 Phase II Trial: uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer Unknown status NCT02960724 Phase 2
33 A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer Unknown status NCT02159703 Phase 2
34 A Pilot Study of Combined Modality Therapy for Recurrent Head and Neck Carcinoma Unknown status NCT00003777 Phase 2 amifostine trihydrate;cisplatin;fluorouracil
35 A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Previously Treated Patients With Advanced Head and Neck Cancer Unknown status NCT00003327 Phase 2 paclitaxel
36 A Pilot Study of Amifostine and Concomitant Cisplatin, Paclitaxel and Radiotherapy in Previously Irradiated, Recurrent Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
37 A Phase I/II Study Using Cisplatin and Gemcitabine (Gemzar) for Advanced Head and Neck Cancer (Squamous Cell Carcinoma) Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
38 Neoadjuvant and Concurrent Chemoradiotherapy Plus Nimotuzumab in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Oropharynx and Hypopharynx Unknown status NCT01516996 Phase 2 docetaxel and cisplatin
39 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
40 Conformal and Intensity Modulated Irradiation for Oropharyngeal Cancer Completed NCT00006360 Phase 1, Phase 2 radioprotection
41 Pilot Study for the Diagnosis of Head and Neck Cancer: Photofrin and Visible Light Completed NCT00002964 Phase 2 porfimer sodium
42 Respiratory-Swallow Training in Veterans With Oropharyngeal Cancer Completed NCT01032928 Phase 2
43 Randomised Pilot Study of Therabite® Versus Wooden Spatula in the Amelioration of Trismus in Head and Neck Cancer Patients. (Trismus Trial) Completed NCT01733797 Phase 2
44 Hyperfractionated Radiotherapy With Concomitant Fluorouracil and Hydroxurea for Intermediate Stage Cancer of the Head and Neck Completed NCT00002951 Phase 2 fluorouracil;hydroxyurea
45 Efficacy Evaluation of the Combination of Valproic Acid and Standard Platinum-based Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Completed NCT01695122 Phase 2 Valproic Acid
46 A Pilot Study to Assess the Effectiveness of the Nicotine Lozenge for Smokeless Tobacco Users Completed NCT00888459 Phase 2 nicotine replacement therapy;placebo NRT
47 Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers? Completed NCT00376987 Phase 2
48 A Phase IIb Cancer Prevention Trial of Celecoxib, a Selective COX-2 Inhibitor, in Oral Leukoplakia Completed NCT00101335 Phase 2 celecoxib
49 Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study Completed NCT00052611 Phase 2 Celecoxib
50 Induction Chemotherapy With Cetuximab, Docetaxel, Cisplatin, and Fluorouracil (ETPF)for Squamous Cell Carcinoma of the Oropharynx That is Operable Stage III-IV Completed NCT00665392 Phase 2 cisplatin;docetaxel;fluorouracil;Cetuximab

Search NIH Clinical Center for Oropharynx Cancer

Genetic Tests for Oropharynx Cancer

Anatomical Context for Oropharynx Cancer

MalaCards organs/tissues related to Oropharynx Cancer:

41
Tongue, Lymph Node, Testes, Tonsil, T Cells, Lung, Breast

The Foundational Model of Anatomy Ontology organs/tissues related to Oropharynx Cancer:

19
The

Publications for Oropharynx Cancer

Articles related to Oropharynx Cancer:

(show top 50) (show all 2628)
# Title Authors PMID Year
1
A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients. 9 38
17378915 2007
2
Laryngeal and oropharyngeal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms. 9 38
9050916 1997
3
Comorbidity in HPV+ and HPV- oropharyngeal cancer patients: A population-based, case-control study. 38
31422200 2019
4
Chronic radiation-associated dysphagia in oropharyngeal cancer survivors: Towards age-adjusted dose constraints for deglutitive muscles. 38
31341972 2019
5
Chronic opioid use in patients undergoing treatment for oropharyngeal cancer. 38
30613983 2019
6
Patterns of care and survival impact of adjuvant chemoradiotherapy for oropharyngeal cancer with intermediate-risk features. 38
31107584 2019
7
Transoral laser microsurgery for treatment of oropharyngeal cancer in 368 patients. 38
31179614 2019
8
Trimodality therapy for oropharyngeal cancer in the TORS era: Is there a cohort that may benefit? 38
30997703 2019
9
Direct medical cost of oropharyngeal cancer among patients insured by Medicaid in Texas. 38
31422209 2019
10
Long-Term Voice and Swallowing Outcomes for Oral and Oropharyngeal Cancer Following Primary or Adjuvant Chemoradiation. 38
31007044 2019
11
Expression of estrogen receptor alpha is associated with pathogenesis and prognosis of human papillomavirus-positive oropharyngeal cancer. 38
31228270 2019
12
Projected oropharyngeal carcinoma incidence among middle-aged US men. 38
31125167 2019
13
A Prospective Cohort Study of Human Papillomavirus-Driven Oropharyngeal Cancers: Implications for Prognosis and Immunisation. 38
31248692 2019
14
Excess HPV-related head and neck cancer in the world trade center health program general responder cohort. 38
30556136 2019
15
Treatment trends in oropharyngeal carcinoma: Surgical technology meets the epidemic. 38
31421473 2019
16
Computed tomography performance in predicting extranodal extension in HPV-positive oropharynx cancer. 38
31411751 2019
17
Incidence trends for upper aerodigestive tract cancers in rural United States counties. 38
30843640 2019
18
Incidental detection of oropharyngeal cancer with fluciclovine PET. 38
31046173 2019
19
Triweekly carboplatin as a potential de-intensification agent in concurrent chemoradiation for early-stage HPV-associated oropharyngeal cancer. 38
31421466 2019
20
American Joint Committee on Cancer eighth edition human papilloma virus positive oropharyngeal cancer staging system: Discordance between clinical and pathological staging systems. 38
30939209 2019
21
Prevalence and characteristics of HPV-driven oropharyngeal cancer in France. 38
31158796 2019
22
Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation. 38
31345397 2019
23
Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer. 38
31088830 2019
24
Evaluating the utility and prevalence of oral rinse and serologic HPV biomarkers for HPV-related oropharyngeal cancer. 38
31420362 2019
25
Radiologic Extranodal Extension Portends Worse Outcome in cN+ TNM-8 Stage I Human Papillomavirus-Mediated Oropharyngeal Cancer. 38
30953712 2019
26
In situ hybridization for high-risk HPV E6/E7 mRNA is a superior method for detecting transcriptionally active HPV in oropharyngeal cancer. 38
31121191 2019
27
High levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) in the serum are associated with poor prognosis in HPV-negative squamous cell oropharyngeal cancer. 38
31240326 2019
28
Identification of an excellent prognosis subset of human papillomavirus associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance. 38
31400196 2019
29
Patient perspectives and treatment regret after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal cancer: Findings from a phase II trial. 38
30958605 2019
30
Tumor Subregion Evolution-based Imaging Features to Assess Early Response and Predict Prognosis in Oropharyngeal Cancer. 38
31420498 2019
31
Intraoperative Margin Control in Transoral Approach for Oral and Oropharyngeal Cancer. 38
30284261 2019
32
Swallowing Function in Survivors of Oropharyngeal Cancer Is Associated With Advanced T Classification. 38
30913911 2019
33
HPV and Oropharyngeal Cancer in the Eighth Edition of the TNM Classification: Pitfalls in Practice. 38
31176088 2019
34
How we improve the transoral resection for oral and oropharyngeal cancer: the CO2 waveguide laser. 38
31115687 2019
35
Priorities of human papillomavirus-associated oropharyngeal cancer patients at diagnosis and after treatment. 38
31345377 2019
36
Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer. 38
31345379 2019
37
HPV-associated oropharyngeal cancer. 38
31403488 2019
38
Effects of jaw exercise intervention timing on outcomes following oral and oropharyngeal cancer surgery: Pilot study. 38
31407421 2019
39
The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiation. 38
31085391 2019
40
Oral testing for high-risk human papillomavirus DNA and E6/E7 messenger RNA in healthy individuals at risk for oral infection. 38
31034590 2019
41
Organ Function Preservation Failure after (Chemo)Radiotherapy in Head and Neck Cancer: A Retrospective Cohort Analysis. 38
31060436 2019
42
Excess Cancer Cases and Medical Costs Due to Suboptimal Human Papillomavirus Vaccination Coverage in California. 38
31295221 2019
43
Human Papillomavirus-Related Oral Cancer: Knowledge and Awareness Among Spanish Dental Students. 38
29748906 2019
44
Induction chemotherapy in head and neck cancers: Results and controversies. 38
31345386 2019
45
Imaging at diagnosis impacts cancer-specific survival among patients with cancer of the oropharynx. 38
31042320 2019
46
Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. 38
31431373 2019
47
SAMHD1 Regulates Human Papillomavirus 16-Induced Cell Proliferation and Viral Replication during Differentiation of Keratinocytes. 38
31391281 2019
48
Validation of the 8th edition UICC/AJCC TNM staging system for HPV associated oropharyngeal cancer patients managed with contemporary chemo-radiotherapy. 38
31288767 2019
49
Culture-independent studies on bacterial dysbiosis in oral and oropharyngeal squamous cell carcinoma: A systematic review. 38
31112880 2019
50
Mutation of chromatin regulators and focal hotspot alterations characterize human papillomavirus-positive oropharyngeal squamous cell carcinoma. 38
30933315 2019

Variations for Oropharynx Cancer

Cosmic variations for Oropharynx Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM33765 AKT1 upper aerodigestive tract,oropharynx,carcinoma,squamous cell carcinoma c.49G>A p.E17K 14:104780214-104780214 0

Expression for Oropharynx Cancer

Search GEO for disease gene expression data for Oropharynx Cancer.

Pathways for Oropharynx Cancer

Pathways related to Oropharynx Cancer according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.63 TP53 KIT ERBB2 EGFR CDKN2A CDH1
2 12.57 TP53 KIT ERBB2 EGFR CDKN2A CDH1
3
Show member pathways
12.47 TP53 ERBB2 EGFR CDKN2A CDH1
4
Show member pathways
12.4 TP53 KIT ERBB2 EGFR CDKN2A CDH1
5
Show member pathways
12.2 TYMP KIT ERBB2 EGFR CDH1
6
Show member pathways
11.68 KIT ERBB2 EGFR
7 11.61 TP53 KRT5 KRT14
8 11.53 TP53 ERBB2 CDKN2A
9 11.48 ERBB2 EGFR CDH1
10 11.32 TP53 EGFR CDKN2A
11 11.28 TP53 NFIB MYBL1 ERBB2
12 11.1 TP53 KIT ERBB2 EGFR
13 10.99 ERBB2 EGFR CDH1
14 10.96 TYMP TP53 ERBB2 EGFR CDKN2A CDH1
15 10.85 TYMP KIT ERBB2 EGFR CDH1

GO Terms for Oropharynx Cancer

Cellular components related to Oropharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratin filament GO:0045095 8.8 KRT7 KRT5 KRT14

Biological processes related to Oropharynx Cancer according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.69 KIT ERBB2 EGFR
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.56 TP53 PLAG1 NFIB MYBL1 MAML2 EGFR
3 positive regulation of MAP kinase activity GO:0043406 9.54 KIT ERBB2 EGFR
4 replicative senescence GO:0090399 9.49 TP53 CDKN2A
5 tongue development GO:0043586 9.48 KIT EGFR
6 hemidesmosome assembly GO:0031581 9.46 KRT5 KRT14
7 somatic stem cell division GO:0048103 9.43 KIT CDKN2A
8 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.4 TP53 EGFR
9 positive regulation of MAPK cascade GO:0043410 9.33 MMP8 KIT ERBB2
10 negative regulation of ERBB signaling pathway GO:1901185 9.32 ERBB2 EGFR
11 negative regulation of immature T cell proliferation in thymus GO:0033088 9.26 ERBB2 CDKN2A
12 positive regulation of gene expression GO:0010628 9.1 TP53 PLAG1 MMP8 KIT ERBB2 CDKN2A

Molecular functions related to Oropharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.33 TP53 SERPINB3 KIT
2 protein phosphatase binding GO:0019903 9.13 TP53 ERBB2 EGFR
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 KIT ERBB2 EGFR

Sources for Oropharynx Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....